• Many Americans' health insurance costs could go up next year.
• Expanded Affordable Care Act subsidies reduced premiums by 44% for many Americans, but are now expiring.
• Without subsidies, premiums could rise by 75% for middle-class Americans.

Middle-class Americans have a new cost to worry about next year: pricier health insurance premiums.

A Biden-era policy expanding eligibility for Affordable Care Act subsidies is set to expire at the end of this year, and there doesn't seem to be much legislative appetite to extend it.

Without those subsidies, out-of-pocket premium costs are set to go up by an average of 75% — imposing another financial burden on Americans and potentially leading to some opting out of coverage altogether.

For some Americans, that could mean a $1,000 or more a year increase in health insurance.

An analysis from the Center on Budget and Policy Priorities found that the enhanced ACA subsidies reduced net premium costs by 44% in 2024, with 93% of those enrolled in the marketplace receiving some form of premium tax credits. In 2024, around 19.3 million Americans enrolled in the marketplace received premium tax credits — the subsidy beefed up by both the American Rescue Plan and the Inflation Reduction Act. How much enrollees received depended on their income and the initial costs of their local plans.

Miranda Yaver, an assistant professor of health policy and management at the University of Pittsburgh and a healthcare fellow at the left-leaning Roosevelt Institute, said that the enhanced subsidies were a "game changer" for Americans who earn too much to qualify for Medicaid, but still may struggle to make ends meet. Business Insider has reported on these workers, known as ALICE or asset-limited, income-constrained, employed. They make too much to qualify for robust assistance, but still struggle to pay their bills.

"If you're piecing together some better-than-minimum-wage jobs, but still hourly jobs, this means that health insurance becomes much more accessible, and that means that you can get the care you need and not have to fear as much about getting sick," Yaver said.

Subsidies expanded who was eligible for ACA health insurance

Some GOP legislators have argued that the policy expanded ACA eligibility too much and offered relief to higher earners while remaining costly to the country. A CBO projection found that making the policy permanent would increase the deficit by $335 billion over the next decade and reduce revenues by $60 billion.

"It is particularly concerning that, by removing the income eligibility limit, some of our nation's highest earners are now eligible for government assistance," Reps. Jason Smith and Jodey Arrington, who respectively chair the House Ways and Means Committee and House Budget Committee, wrote in a 2024 letter. "In certain areas of the country, a family making as much as $599,000 in 2023 could qualify for taxpayer-funded subsidies."

Before the subsidies, only Americans earning between 100% and 400% of the federal poverty line qualified, or between $15,650 and $62,600 based on the current cutoff for a single American.

That 400% limit was expanded under the new structure, meaning that some Americans with ACA coverage were newly eligible to have some premium relief, especially older beneficiaries. Those who made above the 400% line, but were spending over 8.5% of their household income on premiums, became eligible for subsidies.

Christen Young, a visiting fellow at the Brookings Institution's Center on Health Policy, said that those newly eligible Americans saw savings of around $10,000 to $15,000 a year on their premiums.

"Those are the people who are facing particularly large increases in premiums when these enhancements expire," Young said.

A 2024 KFF analysis found, for instance, that Americans making $40,000, or 266% of the federal poverty line, could see their annual premiums increase by $1,247 annually.

"If you take a single parent of one child earning $50,000 a year, that family is saving about $1,700 because of the enhanced premiums. They're going to see their premium increase by about 80% next year when the subsidy enhancements go away," Young said. "A family of four with a household income of $130,000, they're saving $8,000 a year with these enhancements, and they'll see their yearly premium increase by about 60 to 70% next year."

When health insurance costs go up, healthy young people tend to drop coverage

With the expiration looming at the end of the year and premiums expected to rise, many younger and healthier Americans may decide to opt out of coverage. This could, in turn, raise costs even more for those who remain on ACA plans.

Without that younger and healthier group, it becomes more expensive to insure the remaining Americans, and costs go up across the board.

"It's insurance companies correcting for the fact that the people who are going to be enrolled in their plans will probably not be as healthy," Yaver said.

A projection from the nonpartisan Congressional Budget Office found that should the measures lapse, 4.2 million more Americans would be uninsured by 2034.

"One of the things that is really critical to health insurance is being able to essentially spread the risk of insuring people so that we can essentially bring younger and healthier people into the insured population," Yaver said.

There is a possibility that Congress could step in and extend the subsidies, although that looks unlikely, as it would have to have bipartisan approval. The potential end of the subsidies also comes as Americans face a mixed economy: The labor market is seeing shifts, but still chugging along. Inflation is creeping higher, and consumer sentiment is looking dreary — albeit not as low as it has been.

"The average American would have a very difficult time accommodating an unexpected $1,000 expense. That could be a medical, dental expense, home repair, car repair, you name it," Yaver said. "It's very easy to end up spending a thousand dollars in the American healthcare system."

Do you have a story to share about health insurance premiums? Contact this reporter at [email protected].

• Hinge Health and Omada Health sparked fresh hope for digital health IPOs after their strong debuts.
• Some top startups are now preparing for IPOs in 2026 as market uncertainties remain.
• These are the 9 digital health startups that could knock on the IPO door next.

After a long drought, digital health is finally seeing signs of life in the public markets.

In May, physical therapy startup Hinge Health became the first digital health startup to go public in years. Two weeks later, diabetes-focused Omada Health followed with its own IPO.

Both Hinge and Omada saw their shares jump on debut, signaling that investors might be warming up to new digital health public listings. That's welcome news for the late-stage healthcare startups that have been stuck in IPO limbo since the last window slammed shut in 2022.

To get a better sense of which digital health startups might go public next, Business Insider spoke with half a dozen bankers and investors. Those people requested anonymity to speak freely about potential IPO candidates.

The reopening appears more like a crack than a floodgate. Bankers told Business Insider in June that many late-stage healthcare companies are now eyeing IPOs in 2026 or later, due in part to continued market uncertainties.

Some startups are pushing their plans even further out, including Sword Health, a close rival to Hinge Health. CEO Virgilio Bento told TechCrunch last year that a 2025 IPO was a possibility for Sword. But in June, he told the publication his preferred IPO timeline was "maybe 2028."

"We believe market conditions currently lack the stability needed for an IPO to be the kind of accelerator we're looking for," Bento said in a statement to BI.

Whether or not startups decide to take the plunge this year, though, Barclays' head of Americas equity capital markets Rob Stowe told BI in June that Hinge Health's and Omada Health's IPOs send positive signals for the IPO market.

"The market is pretty robust. It's not going to be for all companies, but conditions feel as strong as I've seen them in a while," he said.

Here are 9 healthcare startups that could be knocking on the IPO door next, in alphabetical order.

Aledade

Healthcare startup Aledade could be an important proof point for the public markets on the viability of value-based care enablement technologies, bankers and investors told BI.

Founded in 2014 by former national coordinator for health IT Dr. Farzad Mostashari, Aledade sells data-driven software to independent primary care practices to help them deliver value-based care, improving patient outcomes while lowering costs. The company has steadily grown its presence across Medicare, Medicaid, and commercial insurance programs, now working with over 2,400 practices to support 3 million patients.

To date, Aledade has raised about $660 million in funding from investors like Lightspeed Venture Partners and Venrock, most recently grabbing a $260 million Series F round in June 2023. The company didn't share its valuation at the time.

Aledade said in 2022 that it had been bringing in more earnings than losses, before subtracting for expenses like taxes, for the past two years. In 2023, after its Series F raise, the company said it brought in $475 million in revenue the previous year. Its high revenue and apparent profitability could help position the company for an IPO, although the company will have to differentiate itself from prior value-based care tech listings such as Agilon Health and Privia Health, which have seen their shares decline on the public markets since their 2021 IPOs.

"Aledade is focused on building our business and doing what is good for patients, practices and society, as well as for shareholders, consistent with our public benefit mission. An initial public offering in the future is always possible, based on timing, conditions and financial needs," said Aledade senior VP of communications Julie Bataille in a statement to BI. "However, we don't comment on specific plans and remain focused on the important work of advancing efforts to support independent primary care organizations and their success in value-based care."

Datavant

Health data startup Datavant has been deal hunting this year, and its acquisition spree could hint at a coming IPO.

Datavant, which manages patient data exchanges between providers, payers, and life sciences organizations, spun out of Vivek Ramaswamy's Roivant Sciences in 2017. Datavant last shared its valuation when it merged with Ciox Health in June 2021 in a $7 billion deal, giving it the highest valuation of the startups on this list.

In the past year, Datavant has made four acquisitions, most recently buying health records retrieval company Ontellus in June. Datavant previous acquired venture-backed real-world-evidence startup Aetion in May, and picked up data privacy organization Trace Data and two data analytics products from healthcare AI startup Apixio in September.

Private equity firm New Mountain Capital is Datavant's controlling shareholder. Flare Capital Partners' Parth Desai told Business Insider in December that he expects private-equity-backed healthcare companies to make tuck-in acquisitions in 2025 as they look ahead to potential IPOs in 2026.

"With New Mountain Capital's support as a longtime shareholder that is bullish on our business, we are fortunate to have flexibility as we continue to grow and diversify for our clients," said Datavant CEO Kyle Armbrester in an email to BI. "If market conditions are right, and there's a need for cash to continue to grow the business, a public offering is a potential option we would consider in the future."

Lyra Health

Founded in 2015, Lyra Health is the highest valued startup in mental health. The company was last valued at $5.58 billion in January 2022, when it raised $235 million in Series G funding.

The startup provides mental health services to employers like Morgan Stanley and Zoom, aiming to help clients save thousands of dollars in healthcare claims with its evidence-based treatment. Newly public Hinge Health and Omada Health also contract with employers with similar cost-cutting aims, and their public market debuts could bring Lyra's IPO prospects into focus.

In December, Lyra Health said its cofounder, David Ebersman, would transition from the role of CEO to board chairman following the death of his son in 2024. Jennifer Schulz, most recently the CEO of Experian's North American division, joined Lyra as its new CEO.

Bankers said Schulz's experience in a leadership role at publicly traded Experian could be a boon to Lyra, though the startup may wait until she's further settled in the role to accelerate IPO plans.

Lyra has raised more than $900 million in funding to date from investors including Dragoneer, Coatue, and Salesforce Ventures.

Lyra declined to comment for this story.

Medline

Medline is a long-standing healthcare company, not a startup. But its IPO could make waves across the industry.

Medline was founded in 1966 to manufacture and sell medical supplies to hospitals and clinics. In December, it said it had confidentially filed its S-1 to go public.

Bankers told BI that Medline's IPO would be an important example for the markets of private equity buying a healthcare company and taking it public at a premium. Blackstone, Carlyle, and Hellman & Friedman acquired Medline in 2021 for $34 billion. Reuters reported in December that Medline's IPO could raise over $5 billion and value the company at up to $50 billion.

However, President Donald Trump's shifting tariffs policies could force Medline to delay its public market debut further. Robert Stowe, head of Americas equity capital markets at Barclays, told BI in June that public investors are sensitive to businesses that could be exposed to tariffs. Medline manufactures many products in China, which has been aggressively targeted by Trump's tariff proposals.

Medline didn't respond to requests for comment for this story.

Maven Clinic

Maven, which provides care for women and families through employers and health plans, could provide critical evidence for the market viability of women's health companies with a potential IPO.

Founded in 2014, Maven is backed by leading VC firms including General Catalyst, Sequoia, and Oak HC/FT. The company last raised $125 million in Series F funding in October, led by the private equity firm StepStone Group at a $1.7 billion valuation. The raise boosted Maven's total funding to over $425 million.

The company now says it works with over 2,000 employers and health plans to provide fertility benefits, maternity care, menopause support, and related care.

Investors previously told BI that Maven's IPO, if successful, could help validate the women's health sector for investors and pave the way for more women's health startups to raise funding and find exits.

Maven's strongest signal of its IPO ambitions can be found in its C-Suite. In the first half of the year, the company hired multiple executives with experience guiding companies through public listings.

BI reported in October that Maven let go of its chief financial officer to bring in a new CFO with public market experience. The company said in June it had hired Katie Rooney as its CFO, who previously served as CFO and COO at Alight Solutions through its divestiture from Blackstone-owned Aon Hewitt and its public listing in 2021 via SPAC merger.

Maven also said it had hired a new chief commercial officer, chief legal and administrative officer, and chief communications officer. Maven's new chief legal and administrative officer, Susan Stick, most recently served as general counsel at Life360, leading the company through its 2024 IPO.

Maven declined to comment for this story.

Spring Health

Spring Health has long sought to separate itself from the pack with its AI-powered approach to precision mental healthcare.

Spring Health's algorithms help tailor care plans to an individual's needs, with various types of care provided through its app, such as coaching therapy, psychiatry, and meditation exercises. The company sells its services to employers including Microsoft, Pfizer, and the Coca-Cola Company, as well as health plans.

The Tiger Global-backed startup raised $100 million in Series E funding in July 2024 at a $3.3 billion valuation. According to PitchBook, Spring Health has raised about $466 million since its 2016 founding.

As AI takes off in digital health, Spring says it's embedded AI in its electronic health record system, its patient app, and its real-time analytics for employers. The startup has also expanded the range of its mental health services over the years, most recently digging deeper into pediatric care and support for substance use disorders.

Per Rock Health, mental health was the top-funded clinical indication in 2024 for the sixth year straight, with mental health startups bringing in $1.4 billion last year. Despite high fundraising levels, however, the sector hasn't seen an IPO since 2021. Bankers said Spring Health and Lyra Health are consistently discussed as the most likely two candidates for the next mental health public listings.

Spring Health didn't respond to requests for comment for this story.

Transcarent

Transcarent contracts with employers to provide health navigation and virtual care to employees. The startup looks a lot closer to an exit after a big acquisition earlier this year.

The startup bought the public health benefits company Accolade in a $621 million deal that closed in April. The acquisition looks to have significantly increased Transcarent's customer base and thus made a big contribution to its top line — before the Transcarent deal, Accolade said it contracted with over 1,400 employers and health plans, and the company reported $414 million in revenue in the fiscal year 2024. Now, with Accolade on board, Transcarent says it works with over 1,700 employers and health plans. Transcarent hasn't publicly shared its revenue.

The Accolade acquisition was financed by Transcarent investors including General Catalyst and CEO Glen Tullman's 62 Ventures, cash on Transcarent's balance sheet, and debt provided by JP Morgan. Transcarent has raised about $450 million since its 2020 founding, including $126 million in a Series D funding round in May 2024 at a $2.2 billion valuation.

Tullman has by far the most experience with taking companies public of the CEOs on this list. Before Transcarent, he led three companies through public listings — Livongo, Allscripts, and Enterprise Systems. His success with Livongo, the diabetes care company he founded, stands out as a rare example of blockbuster digital health returns; Livongo went public in 2019 at a $2.5 billion valuation, before being acquired by Teladoc the next year for $18.5 billion, at the time the biggest deal ever in the digital health market.

That experience could set Transcarent up to pursue an IPO when market conditions look favorable. Tullman told MedCity News in May 2024 that he had "no interest" in selling the company, but would consider an IPO in the future.

Transcarent will have to separate itself from previous care navigation IPOs, however, including Health Catalyst, whose stock has declined more than 85% since its 2019 IPO. It'll also need to contend with Accolade's cash burn, since the health benefits company reported a net loss of $100 million in the fiscal year 2024.

In a statement to BI, Tullman said Transcarent is focused on integrating its solutions to bring its AI-powered platform, called WayFinding, to more members and employers to make healthcare more accessible and affordable.

"At Transcarent, our priority is meeting the needs of our Members and delivering measurable results for our clients. If we do those things well, the rest will follow," Tullman said.

Virta Health

Omada Health's June IPO could set up diabetes care peer Virta Health to follow in its footsteps.

Founded in 2014, Virta Health made its name in virtual diabetes care, helping patients reverse type 2 diabetes through personalized, low-carb nutrition plans. It's expanding quickly into obesity treatment and added GLP-1 prescriptions like Ozempic for weight loss in January. The company previously prescribed GLP-1s only for diabetes.

CEO Sami Inkinen told Business Insider in January that Virta was bringing in over $100 million in annual recurring revenue, up 60% from the year before. He said he expected even faster growth in 2025, driven by surging demand for Virta's weight-loss care.

"An IPO is the next milestone for us," Inkinen said at the time. He declined to provide details on Virta's potential IPO timing, but said the company wants to be profitable before it braves the public markets.

Virta was last valued at $2 billion in 2021, when it raised $133 million in Series E funding led by Tiger Global. Inkinen said in January that Virta would be profitable by the end of 2025.

In a conversation with BI at the end of June, Inkinen declined to share specifics about a potential Virta IPO or a likely timeline for its public listing. However, he said it's always been his plan for Virta to be an independent public company, adding that Virta is tracking towards that goal.

Inkinen said Virta's growth rate is accelerating and that the company is ahead of its financial targets for the year. He's not stressing about timing the market, he said.

"The very best investor relations is fantastic financials. If you have those as a company, that's the best marketing before IPO, and for the IPO and beyond. Build a great business, and the rest will take care of itself," he said.

Zelis

Zelis was started 30 years ago under the name Stratose, later merging with GlobalCare and Pay-Plus Solutions to create Zelis Healthcare. The company now sells healthtech software to payers and providers to manage medical claims and process electronic payments.

Bankers told Business Insider that Zelis's business is stable with strong economics that could position it well for an IPO.

Zelis's profile isn't too dissimilar from Waystar, a private-equity-backed healthcare payments company that went public in June 2024 with an initial market cap of about $3.5 billion. Since then, Waystar's stock has risen about 88%, and as of late June, the company boasts a $6.7 billion market cap. That success could set Zelis up to follow in Waystar's footsteps.

Zelis announced it had sold a minority stake for an undisclosed price in December, led by Mubadala Capital and including Norwest and HarbourVest. The recent capital raise could push Zelis's IPO back if the company doesn't see a significant financial benefit to going public, bankers said.

Zelis declined to comment for this story.

• At 26, Kevin Choi lost half his vision to glaucoma — a progressive eye disease.
• The diagnosis sparked the start of his healthtech startup, which uses AI to detect critical diseases.
• Choi said AI can speed up and simplify screening, but it's no substitute for a doctor.

At 26, Kevin Choi got a diagnosis that changed his life: glaucoma.

It's a progressive eye disease that damages the optic nerve, often without symptoms until it's too late. By the time doctors caught it, Choi had lost half his vision.

An engineer by training — and a former rifleman in South Korea's Marine Corps — Choi thought he had a solid handle on his health.

"I was really frustrated I didn't notice that," he said.

The 2016 diagnosis still gives him "panic." But it also sparked something big.

That year, Choi teamed up with his doctor, a vitreoretinal surgeon, to cofound Mediwhale, a South Korea-based healthtech startup.

Their mission is to use AI to catch diseases before symptoms show up and cause irreversible harm.

"I'm the person who feels the value of that the most," Choi said.

The tech can screen for cardiovascular, kidney, and eye diseases through non-invasive retinal scans.

Mediwhale's technology is primarily used in South Korea, and hospitals in Dubai, Italy, and Malaysia have also adopted it.

Mediwhale said in September that it had raised $12 million in its Series A2 funding round, led by Korea Development Bank.

AI can help with fast, early screening

Choi believes AI is most powerful in the earliest stage of care: screening.

AI, he said, can help healthcare providers make faster, smarter decisions — the kind that can mean the difference between early intervention and irreversible harm.

In some conditions, "speed is the most important," Choi said. That's true for "silent killers" like heart and kidney disease, and progressive conditions like glaucoma — all of which often show no early symptoms but, unchecked, can lead to permanent damage.

For patients with chronic conditions like diabetes or obesity, the stakes are even higher. Early complications can lead to dementia, liver disease, heart problems, or kidney failure.

The earlier these risks are spotted, the more options doctors — and patients — have.

Choi said Mediwhale's AI makes it easier to triage by flagging who's low-risk, who needs monitoring, and who should see a doctor immediately.

Screening patients at the first point of contact doesn't require "very deep knowledge," Choi said. That kind of quick, low-friction risk assessment is where AI shines.

Mediwhale's tool lets patients bypass traditional procedures — including blood tests, CT scans, and ultrasounds — when screening for cardiovascular and kidney risks.

Choi also said that when patients see their risks visualized through retinal scans, they tend to take it more seriously.

AI won't replace doctors

Despite his belief in AI's power, Choi is clear: It's not a replacement for doctors.

Patients want to hear a human doctor's opinion and reassurance.

Choi also said that medicine is often messier than a clean dataset. While AI is "brilliant at solving defined problems," it lacks the ability to navigate nuance.

"Medicine often requires a different dimension of decision-making," he said.

For example: How will a specific treatment affect someone's life? Will they follow through? How is their emotional state affecting their condition? These are all variables that algorithms still struggle to read, but doctors can pick up. These insights "go beyond simple data points," Choi said.

And when patients push back — say, hesitating to start a new medication — doctors are trained to both understand why and guide them.

They are able to "navigate patients' irrational behaviours while still grounding decisions in quantitative data," he said.

"These are complex decision-making processes that extend far beyond simply processing information."

• Hospitals face frequent disruptions in inventory for supplies like IV fluids and medications.
• Mayo Clinic, Cleveland Clinic, and Rush University Medical Center leaders talk about managing that with AI.
• This article is part of "How AI Is Changing Everything: Supply Chain," a series on innovations in logistics.

When Hurricane Helene hit North Carolina in late September, it caused more than $59 billion in damages.

Among those businesses damaged was one of the US's main manufacturers of IV fluids, used to rehydrate patients and give them medicine. The resultant shortage forced hospitals to conserve and reduce their use of IV fluids, which led to canceled surgeries and treatment delays.

Such disruptions to hospital inventory have long been hard to predict and difficult for hospitals to navigate. At the same time, keeping too much of a given item on hand is wasteful. In 2019, hospitals spent about $25.7 billion on supplies that they didn't need, the consulting firm Navigant found in a study of over 2,100 hospitals — about $12.1 million for an average hospital.

To reduce waste, while ensuring providers have the medical supplies they need, some leading hospital systems are using automation, predictive analytics, and other forms of artificial intelligence to manage inventory.

Business Insider asked supply chain managers from three systems — the Cleveland Clinic, the Mayo Clinic, and Rush University Medical Center — about how they use machine learning, generative AI, sensors, and robotics to anticipate shortages and help with contracting and ordering.

The following has been edited for length and clarity.

Business Insider: What are some of the most effective and innovative ways that you're making use of AI?

Joe Dudas, Mayo Clinic's division chair of supply chain strategy: We've deployed autonomous delivery and robotic warehouse fulfilment — robots that pick orders.

We're advancing our algorithms for auto-replenishment to be even more accurate. We're also using AI to explore savings opportunities and understand the sustainability of those opportunities over the length of an agreement, based, for example, on demand.

We're doing advanced analytics in high-spend categories — we're just getting a lot smarter about what's happening with a little bit more precision. Even our expense management, we're looking at profit and loss, and supply expense, to understand what's happening from a budgetary perspective. Based on the present and what's happened in the past, we can look forward with some degree of accuracy.

Geoff Gates, Cleveland Clinic's senior director of supply chain management: In some of our tools, instead of having someone click lots of buttons and type data into 20 or more fields, for example, we have been able to automate that process with AI, which saves employees 20 minutes every time. Those are the tasks that are the biggest benefit from a pure efficiency standpoint — they let people focus on other things.

We also use AI for document recognition and have been using it to manage invoices through our ERP inventory-management system for the last four years. If a medical-supply rep has a bill sheet that needs to get processed — to create a purchase order — the rep submits it, and our tool automatically creates a requisition.

With distribution, our goal is to create a better view of what we have within our health system and the hospital. Our goal with key suppliers is to be able to see which supplies they have in their warehouses and to predict disruptions. For instance, if we can see that a supplier doesn't have a shipment coming in, the system would alert us that we'll have a problem in two weeks.

Jeremy Strong, Rush University Medical Center's vice president of supply chain: For inventory management, we have weighted bin systems in all heavy-volume areas. When a nurse takes something out and puts something back in, we know it.

Once we implemented that, we could start to be proactive. We have a system that includes our distributor's data about inventory coming into their distribution center. They can see where our utilization patterns are changing. Then AI reviews all that. A back-order dashboard creates alerts when automatic supply-refill levels across the system are low, inventory is low at the distribution center, or shipments from manufacturers are taking longer than anticipated. We can anticipate that we're going to run out in a week from now or going to have a back-order problem.

We also use it in contract management. When a contract is loaded in, AI will send it to the category manager with a summary and potential clauses to review. It can also automatically send contracts to the cybersecurity team for approval. If it has patient information, it sends it to the risk lawyers. If it has indemnification, it sends it to our regular lawyers.

What are some of the advantages of automation that your system has realized?

Dudas: Our automation gives us agility. We can see things sooner and adjust faster because of our technology but also because of our talent.

Somebody asked me the other day, "Where are you advancing?" I said, "We're not advancing. We're keeping up with all of the curveballs we get thrown on a day-to-day basis."

Gates: At this point, the tools have touched almost everyone in the supply chain. Even a specific process that only impacts one or two people who were doing those tasks allows us to be more efficient and accurate.

Strong: The goal was to move from being reactive and putting out fires to being more predictive, to prevent fires from happening, see things ahead of time, and be more efficient.

We've also sped up contract review. We cut the time it takes to review them in half and more than doubled the number of reviews each contract gets.

What advice do you have for other companies interested in implementing AI to streamline inventory?

Dudas: Recognize that you can't do everything yourself. Even as big as our organization is, it's not big enough. Scale is your friend in the supply chain.

Gates: Some things weren't necessarily the biggest opportunities to start with, but they were low-risk processes that gave us the skillset needed to leverage AI.

We're most focused on finding the right solution for the problem rather than forcing a solution.

Strong: The best tasks or processes to tackle are ones that are repetitive or require pulling and summarizing data from multiple digital sources. Tackle these, and you can gain efficiencies, improve productivity, and be proactive.